Advanced seminoma and nonseminoma

SIU/ICUD consensus meeting on germ cell tumors (GCT), Shanghai 2009

Hans Joachim Schmoll, Susanne Osanto, Koji Kawai, Lawrence Einhorn, Karim Fizazi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of cisplatin-based combination chemotherapy has led to a dramatic improvement in the cure rate of patients with metastatic germ cell tumors (GCTs). With high complete response (CR) rates achieved in approximately 80% of patients with advanced testicular cancer after standard first-line cisplatin-based chemotherapy. Thereafter, the goals of various trials were to reduce the chemotherapy toxicity by limiting the number of chemotherapy cycles, the duration of therapy, and reducing the doses of, or even omitting, individual cytotoxic drugs, while maintaining efficacy, or to investigate the potential role of carboplatin as single agent or combined with etoposide and bleomycin for advanced seminoma. From prospective randomized trials and available data from additional sources, a European standard has been defined in several consensus conferences, 1-3 with the most recent consensus conference published by the European Society for Medical Oncology Consensus Group. 4,5 These international guidelines were developed from the previous published guidelines and data from available current trials. The principles of evidence-based medicine were scored (score 1-4) using a modified version of the Oxford levels of evidence and are listed in the present report in brackets. Draft guidelines were presented at an International Consensus in Urological Disease (ICUD) meeting (Shanghai, November 2009). The writing committee compiled the results of the discussion. All participants agreed to this final update.

Original languageEnglish (US)
JournalUrology
Volume78
Issue number4 SUPPL.
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Urologic Diseases
Seminoma
Germ Cell and Embryonal Neoplasms
Guidelines
Drug Therapy
Cisplatin
Information Storage and Retrieval
Evidence-Based Medicine
Carboplatin
Bleomycin
Testicular Neoplasms
Etoposide
Combination Drug Therapy
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Advanced seminoma and nonseminoma : SIU/ICUD consensus meeting on germ cell tumors (GCT), Shanghai 2009. / Schmoll, Hans Joachim; Osanto, Susanne; Kawai, Koji; Einhorn, Lawrence; Fizazi, Karim.

In: Urology, Vol. 78, No. 4 SUPPL., 10.2011.

Research output: Contribution to journalArticle

Schmoll, Hans Joachim ; Osanto, Susanne ; Kawai, Koji ; Einhorn, Lawrence ; Fizazi, Karim. / Advanced seminoma and nonseminoma : SIU/ICUD consensus meeting on germ cell tumors (GCT), Shanghai 2009. In: Urology. 2011 ; Vol. 78, No. 4 SUPPL.
@article{d9a015828407428fa22bdd746da1fb38,
title = "Advanced seminoma and nonseminoma: SIU/ICUD consensus meeting on germ cell tumors (GCT), Shanghai 2009",
abstract = "The use of cisplatin-based combination chemotherapy has led to a dramatic improvement in the cure rate of patients with metastatic germ cell tumors (GCTs). With high complete response (CR) rates achieved in approximately 80{\%} of patients with advanced testicular cancer after standard first-line cisplatin-based chemotherapy. Thereafter, the goals of various trials were to reduce the chemotherapy toxicity by limiting the number of chemotherapy cycles, the duration of therapy, and reducing the doses of, or even omitting, individual cytotoxic drugs, while maintaining efficacy, or to investigate the potential role of carboplatin as single agent or combined with etoposide and bleomycin for advanced seminoma. From prospective randomized trials and available data from additional sources, a European standard has been defined in several consensus conferences, 1-3 with the most recent consensus conference published by the European Society for Medical Oncology Consensus Group. 4,5 These international guidelines were developed from the previous published guidelines and data from available current trials. The principles of evidence-based medicine were scored (score 1-4) using a modified version of the Oxford levels of evidence and are listed in the present report in brackets. Draft guidelines were presented at an International Consensus in Urological Disease (ICUD) meeting (Shanghai, November 2009). The writing committee compiled the results of the discussion. All participants agreed to this final update.",
author = "Schmoll, {Hans Joachim} and Susanne Osanto and Koji Kawai and Lawrence Einhorn and Karim Fizazi",
year = "2011",
month = "10",
doi = "10.1016/j.urology.2011.08.001",
language = "English (US)",
volume = "78",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Advanced seminoma and nonseminoma

T2 - SIU/ICUD consensus meeting on germ cell tumors (GCT), Shanghai 2009

AU - Schmoll, Hans Joachim

AU - Osanto, Susanne

AU - Kawai, Koji

AU - Einhorn, Lawrence

AU - Fizazi, Karim

PY - 2011/10

Y1 - 2011/10

N2 - The use of cisplatin-based combination chemotherapy has led to a dramatic improvement in the cure rate of patients with metastatic germ cell tumors (GCTs). With high complete response (CR) rates achieved in approximately 80% of patients with advanced testicular cancer after standard first-line cisplatin-based chemotherapy. Thereafter, the goals of various trials were to reduce the chemotherapy toxicity by limiting the number of chemotherapy cycles, the duration of therapy, and reducing the doses of, or even omitting, individual cytotoxic drugs, while maintaining efficacy, or to investigate the potential role of carboplatin as single agent or combined with etoposide and bleomycin for advanced seminoma. From prospective randomized trials and available data from additional sources, a European standard has been defined in several consensus conferences, 1-3 with the most recent consensus conference published by the European Society for Medical Oncology Consensus Group. 4,5 These international guidelines were developed from the previous published guidelines and data from available current trials. The principles of evidence-based medicine were scored (score 1-4) using a modified version of the Oxford levels of evidence and are listed in the present report in brackets. Draft guidelines were presented at an International Consensus in Urological Disease (ICUD) meeting (Shanghai, November 2009). The writing committee compiled the results of the discussion. All participants agreed to this final update.

AB - The use of cisplatin-based combination chemotherapy has led to a dramatic improvement in the cure rate of patients with metastatic germ cell tumors (GCTs). With high complete response (CR) rates achieved in approximately 80% of patients with advanced testicular cancer after standard first-line cisplatin-based chemotherapy. Thereafter, the goals of various trials were to reduce the chemotherapy toxicity by limiting the number of chemotherapy cycles, the duration of therapy, and reducing the doses of, or even omitting, individual cytotoxic drugs, while maintaining efficacy, or to investigate the potential role of carboplatin as single agent or combined with etoposide and bleomycin for advanced seminoma. From prospective randomized trials and available data from additional sources, a European standard has been defined in several consensus conferences, 1-3 with the most recent consensus conference published by the European Society for Medical Oncology Consensus Group. 4,5 These international guidelines were developed from the previous published guidelines and data from available current trials. The principles of evidence-based medicine were scored (score 1-4) using a modified version of the Oxford levels of evidence and are listed in the present report in brackets. Draft guidelines were presented at an International Consensus in Urological Disease (ICUD) meeting (Shanghai, November 2009). The writing committee compiled the results of the discussion. All participants agreed to this final update.

UR - http://www.scopus.com/inward/record.url?scp=80054733902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054733902&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2011.08.001

DO - 10.1016/j.urology.2011.08.001

M3 - Article

VL - 78

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4 SUPPL.

ER -